These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

375 related articles for article (PubMed ID: 12181048)

  • 41. Generation of EBV-specific CTLs suitable for adoptive immunotherapy of EBV-associated lymphoproliferative disease following allogeneic transplantation.
    Hoffmann T; Russell C; Vindelov L
    APMIS; 2002 Feb; 110(2):148-57. PubMed ID: 12064870
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Patient-tailored adoptive immunotherapy with EBV-specific T cells from related and unrelated donors.
    Bonifacius A; Lamottke B; Tischer-Zimmermann S; Schultze-Florey R; Goudeva L; Heuft HG; Arseniev L; Beier R; Beutel G; Cario G; Fröhlich B; Greil J; Hansmann L; Hasenkamp J; Höfs M; Hundsdoerfer P; Jost E; Kafa K; Kriege O; Kröger N; Mathas S; Meisel R; Nathrath M; Putkonen M; Ravens S; Reinhardt HC; Sala E; Sauer MG; Schmitt C; Schroers R; Steckel NK; Trappe RU; Verbeek M; Wolff D; Blasczyk R; Eiz-Vesper B; Maecker-Kolhoff B
    J Clin Invest; 2023 Jun; 133(12):. PubMed ID: 37159273
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A phase I-II trial to examine the toxicity of CMV- and EBV-specific cytotoxic T lymphocytes when used for prophylaxis against EBV and CMV disease in recipients of CD34-selected/T cell-depleted stem cell transplants.
    Lucas KG; Sun Q; Burton RL; Tilden A; Vaughan WP; Carabasi M; Salzman D; Ship A
    Hum Gene Ther; 2000 Jul; 11(10):1453-63. PubMed ID: 10910142
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Adoptive immunotherapy for EBV-associated malignancies.
    Gottschalk S; Heslop HE; Rooney CM
    Leuk Lymphoma; 2005 Jan; 46(1):1-10. PubMed ID: 15621775
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Adoptive transfer of cytotoxic T lymphocytes for the treatment of transplant-associated lymphoma.
    Boyle TJ; Berend KR; DiMaio JM; Coles RE; Via DF; Lyerly HK
    Surgery; 1993 Aug; 114(2):218-25; discussion 226. PubMed ID: 8393595
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Assessment and characterization of the cytolytic T lymphocyte response against Epstein-Barr virus in patients with non-Hodgkin's lymphoma after autologous peripheral blood stem cell transplantation.
    Nolte A; Buhmann R; Straka C; Emmerich B; Hallek M
    Bone Marrow Transplant; 1998 May; 21(9):909-16. PubMed ID: 9613783
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The generation and characterization of LMP2-specific CTLs for use as adoptive transfer from patients with relapsed EBV-positive Hodgkin disease.
    Bollard CM; Straathof KC; Huls MH; Leen A; Lacuesta K; Davis A; Gottschalk S; Brenner MK; Heslop HE; Rooney CM
    J Immunother; 2004; 27(4):317-27. PubMed ID: 15235393
    [TBL] [Abstract][Full Text] [Related]  

  • 48. EBV-related lymphomas: new approaches to treatment.
    Kanakry JA; Ambinder RF
    Curr Treat Options Oncol; 2013 Jun; 14(2):224-36. PubMed ID: 23549980
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Towards gene therapy for EBV-associated posttransplant lymphoma with genetically modified EBV-specific cytotoxic T cells.
    Ricciardelli I; Blundell MP; Brewin J; Thrasher A; Pule M; Amrolia PJ
    Blood; 2014 Oct; 124(16):2514-22. PubMed ID: 25185261
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Treatment of posttransplant lymphoproliferative disease in the central nervous system of a lung transplant recipient using allogeneic leukocytes.
    Emanuel DJ; Lucas KG; Mallory GB; Edwards-Brown MK; Pollok KE; Conrad PD; Robertson KA; Smith FO
    Transplantation; 1997 Jun; 63(11):1691-4. PubMed ID: 9197369
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cytotoxic T lymphocyte therapy with donor T cells prevents and treats adenovirus and Epstein-Barr virus infections after haploidentical and matched unrelated stem cell transplantation.
    Leen AM; Christin A; Myers GD; Liu H; Cruz CR; Hanley PJ; Kennedy-Nasser AA; Leung KS; Gee AP; Krance RA; Brenner MK; Heslop HE; Rooney CM; Bollard CM
    Blood; 2009 Nov; 114(19):4283-92. PubMed ID: 19700662
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients.
    Heslop HE; Slobod KS; Pule MA; Hale GA; Rousseau A; Smith CA; Bollard CM; Liu H; Wu MF; Rochester RJ; Amrolia PJ; Hurwitz JL; Brenner MK; Rooney CM
    Blood; 2010 Feb; 115(5):925-35. PubMed ID: 19880495
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Epstein-Barr virus-specific cytotoxic T-lymphocytes for adoptive immunotherapy of post-transplant lymphoproliferative disease.
    Burns DM; Crawford DH
    Blood Rev; 2004 Sep; 18(3):193-209. PubMed ID: 15183903
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Treatment of Epstein-Barr-virus-positive post-transplantation lymphoproliferative disease with partly HLA-matched allogeneic cytotoxic T cells.
    Haque T; Wilkie GM; Taylor C; Amlot PL; Murad P; Iley A; Dombagoda D; Britton KM; Swerdlow AJ; Crawford DH
    Lancet; 2002 Aug; 360(9331):436-42. PubMed ID: 12241714
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Adoptive immunotherapy for Hodgkin's lymphoma.
    Kennedy-Nasser AA; Bollard CM; Rooney CM
    Int J Hematol; 2006 Jun; 83(5):385-90. PubMed ID: 16787867
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Good manufacturing practice-grade cytotoxic T lymphocytes specific for latent membrane proteins (LMP)-1 and LMP2 for patients with Epstein-Barr virus-associated lymphoma.
    Bollard CM; Gottschalk S; Helen Huls M; Leen AM; Gee AP; Rooney CM
    Cytotherapy; 2011 May; 13(5):518-22. PubMed ID: 21361747
    [No Abstract]   [Full Text] [Related]  

  • 57. Enhancing the in vivo expansion of adoptively transferred EBV-specific CTL with lymphodepleting CD45 monoclonal antibodies in NPC patients.
    Louis CU; Straathof K; Bollard CM; Gerken C; Huls MH; Gresik MV; Wu MF; Weiss HL; Gee AP; Brenner MK; Rooney CM; Heslop HE; Gottschalk S
    Blood; 2009 Mar; 113(11):2442-50. PubMed ID: 18971421
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Treatment of Epstein-Barr virus-associated malignancies with specific T cells.
    Gottschalk S; Heslop HE; Roon CM
    Adv Cancer Res; 2002; 84():175-201. PubMed ID: 11883527
    [TBL] [Abstract][Full Text] [Related]  

  • 59. 'Off-the-shelf' allogeneic antigen-specific adoptive T-cell therapy for the treatment of multiple EBV-associated malignancies.
    Sinha D; Srihari S; Beckett K; Le Texier L; Solomon M; Panikkar A; Ambalathingal GR; Lekieffre L; Crooks P; Rehan S; Neller MA; Smith C; Khanna R
    J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33589524
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation.
    Rooney CM; Smith CA; Ng CY; Loftin S; Li C; Krance RA; Brenner MK; Heslop HE
    Lancet; 1995 Jan; 345(8941):9-13. PubMed ID: 7799740
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.